aTyr Pharma reaches FDA alignment on Phase 3 efzofitimod study
Tweet Send to a Friend
aTyr Pharma, Inc. (Nasdaq: ATYR) announced it has reached alignment with the U.S. Food and Drug Administration on the protocol ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


